News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Conference News AHA 2016 No CV Safety Differences for COX-2 Inhibitor vs Other NSAIDs in PRECISION Shelley Wood November 13, 2016
News Opinion Editor's Corner TCT 2016 My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway Shelley Wood November 07, 2016
News Conference News TCT 2016 ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions L.A. McKeown November 07, 2016
News Conference News Watchman, Amulet LAA Closure Devices Carry Low Complication Rates Todd Neale November 04, 2016
News Industry News Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016 November 03, 2016
Presentation TCT 2016 WATCHMAN US POST-APPROVAL STUDY: Multicenter, Prospective, Registry Results With a Left Atrial Appendage Closure Device for Stroke Prevention in Patients With Atrial Fibrillation Presenter: Martin B. Leon, Louis A. Cannon, David R. Holmes Jr. November 02, 2016
Presentation TCT 2016 Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen November 01, 2016
Presentation TCT 2016 Anticipating FDA approval of the Amplatzer PFO Occluder: Indications, Rational Dispersion of Technology, and Post-Approval Studies Presenter: Eustaquio Maria Onorato, Richard Smalling November 01, 2016
Presentation TCT 2016 Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant November 01, 2016
Presentation TCT 2016 Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon November 01, 2016
Presentation TCT 2016 Possible Approval Pathways for New Mitral and Tricuspid Valve Therapies Presenter: Matthew G. Hillebrenner, Michael J. Mack, John C Laschinger November 01, 2016
Presentation TCT 2016 FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben November 01, 2016
Presentation TCT 2016 Industry Perspectives: Balancing Innovation and Robust Clinical Evidence Generation With Declining DES Use and Reimbursement Presenter: Michael C. John, Gregg W. Stone, Jason R. Weidman November 01, 2016
Presentation TCT 2016 Bioresorbable Scaffolds - Lessons Learned From the ABSORB Odyssey: Industry Perspectives Presenter: Michael C. John, Gregg W. Stone, Chuck Simonton November 01, 2016
Presentation TCT 2016 FDA Perspectives on Short DAPT IDE Trials Presenter: Michael C. John, Gregg W. Stone, Andrew Farb November 01, 2016
Presentation TCT 2016 FDA Regulatory Considerations for Novel and Not-So-Novel New Metallic DES and Bioresorbable Scaffolds Presenter: Michael C. John, Gregg W. Stone, P.F. Adrian Magee November 01, 2016
Presentation TCT 2016 From Pre-Clinical to Post-Approval: The Essential Role of Imaging Presenter: Stephen H. Little, G. Burkhard Mackensen, Neil J. Weissman November 01, 2016
News Conference News TCT 2016 Final RESPECT Data Support PFO Closure for Cryptogenic Stroke Prevention Yael L. Maxwell November 01, 2016
Presentation TCT 2016 Benefit of Supersaturated Oxygen for Large Anterior STEMI: From ICI-HOT to Approval? Presenter: Cindy L. Grines, Holger Thiele, Gregg W. Stone October 31, 2016